Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes |
| |
Authors: | Willard Melinda D Lajiness Mary E Wulur Isabella H Feng Bo Swearingen Michelle L Uhlik Mark T Kinzler Kenneth W Velculescu Victor E Sjöblom Tobias Markowitz Sanford D Powell Steven M Vogelstein Bert Barber Thomas D |
| |
Institution: | Department of Translational Science, Lilly Research Laboratories, Indianapolis, Indiana 46225, USA. willardme@lilly.com |
| |
Abstract: | The roles of cholecystokinin 2 receptor (CCK2R) in numerous physiologic processes in the gastrointestinal tract and central nervous system are well documented. There has been some evidence that CCK2R alterations play a role in cancers, but the functional significance of these alterations for tumorigenesis is unknown. We have identified six mutations in CCK2R among a panel of 140 colorectal cancers and 44 gastric cancers. We show that these mutations increase receptor activity, activate multiple downstream signaling pathways, increase cell migration, and promote angiogenesis. Our findings suggest that somatic mutations in CCK2R may promote tumorigenesis through deregulated receptor activity and highlight the importance of evaluating CCK2R inhibitors to block both the normal and mutant forms of the receptor. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|